Loading organizations...
§ Private Profile · Framingham, MA, USA
PerSeptive Biosystems is a company.
Key people at PerSeptive Biosystems.
PerSeptive Biosystems was founded in 1989 by Noubar Afeyan (CEO and Founder).
PerSeptive Biosystems develops and manufactures advanced bio-instrumentation and specialized consumables for the life sciences industry. Its core offerings include integrated systems for biomolecule purification, analysis, and synthesis. Leveraging technologies like perfusion chromatography and mass spectrometry, the company's products enable efficient, high-throughput processing crucial for drug discovery and biopharmaceutical development.
Founded in 1988 by biotechnologist Noubar Afeyan, PerSeptive Biosystems originated from his recognition of critical technological gaps in biomolecule handling. Afeyan identified the need for sophisticated tools to accelerate research and development in the rapidly evolving biopharmaceutical sector. This insight led to establishing a company dedicated to comprehensive solutions for these complex challenges.
The company primarily serves researchers and developers across the biopharmaceutical and academic life sciences sectors. PerSeptive Biosystems delivers robust, scalable solutions enhancing laboratory and manufacturing workflows. Its vision centers on advancing biotechnology capabilities through innovative instrumentation, aiming to accelerate the discovery and production of new treatments and therapies.
Key people at PerSeptive Biosystems.
PerSeptive Biosystems was founded in 1989 by Noubar Afeyan (CEO and Founder).
PerSeptive Biosystems was a biotechnology company that developed technologies for the purification, analysis, and synthesis of biomolecules, targeting the biopharmaceutical sector to reduce time and costs in drug development and manufacturing.[1] It served life scientists in pharmaceutical, diagnostic, and biotechnology companies with tools like mass spectrometry and chromatography systems.[1][4] Founded in 1989 (with some sources noting 1988) and based in Foster City, California (initially Massachusetts), the company operated until its acquisition in 1998 by Applera/Applied Biosystems (part of PerkinElmer's lineage), marking the end of its independent growth.[1][2][3][5][6]
PerSeptive Biosystems emerged in the late 1980s amid rising demand for advanced biomolecule analysis tools, initially operating as Synosys before rebranding.[1] Founded around 1988-1989, it was headquartered first in Massachusetts, later shifting to Foster City, California, focusing on laboratory instrumentation for biopharma research.[1][5][6] Key early traction came from innovations in protein analysis, chromatography, and mass spectrometry, positioning it as a specialist in high-throughput biomolecule handling.[1][4] A pivotal moment arrived in January 1998 when it was acquired by Applera Corporation (incorporating PE Biosystems), integrating its technologies into larger life sciences platforms under PerkinElmer's eventual umbrella.[1][2][3]
PerSeptive Biosystems rode the 1990s biotech boom, fueled by genomics and proteomics advances that demanded faster biomolecule tools amid the Human Genome Project era.[2][3] Its timing aligned with surging biopharma investments, where protein analysis became critical for drug development, influencing PerkinElmer's expansion into diagnostics and life sciences.[2][3] Market forces like rising R&D costs favored its efficiency-focused innovations, helping consolidate the analytical instruments sector—PerkinElmer's acquisitions, including PerSeptive, shaped ecosystem standards for high-throughput screening and testing.[2]
As an acquired entity fully integrated into PerkinElmer's portfolio by the early 2000s, PerSeptive Biosystems' legacy endures in modern biomolecule analysis tools still used in biopharma R&D.[2][3] Its influence persists through evolved platforms driving drug discovery, with trends like AI-enhanced proteomics and personalized medicine likely amplifying its foundational tech. Looking ahead, expect continued relevance in PerkinElmer's diagnostics and genomics arms, underscoring how early innovators like PerSeptive enabled today's biotech efficiency.
